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INTRODUCTION
Benign diseases of the prostate, and the
urinary and pelvic symptoms associated
with them, are common in the generalmale
population. Even though many men will
never experience bothersome symptoms
and many will be undiagnosed, benign
prostate diseases result in considerable
demands on health services.1,2 Despite this,
knowledge of the natural history of benign
prostatic diseases is far from complete, and
uncertainty persists with regard to
prognosis.3
In the community, men affected by
benign prostate disease are often
concerned about whether they have an
increased risk of prostate cancer.4 Men with
lower urinary tract symptoms consistent
with benign disease are more likely to
expect to be tested for cancer than those
without.5 Prostate cancer is the most
common cancer in men, accounting for
some 24% of new cancer cases in men in
the UK.6
The nature of the relationship between
benign prostate disease and prostate
cancer remains controversial.7 Both benign
and malignant prostate disease are
hormone dependent, their incidence
increases with age, and they are often
found in the same patients.8
Epidemiological relationships are well
established: autopsy data suggest that
most prostate cancers (83%) develop in
men in whom benign prostatic hyperplasia
(BPH) is also present, and a 67%
prevalence of BPH has been reported in
men whose prostate-specific antigen (PSA)
levels indicate an increasedprostate cancer
risk.9 There is also increasing evidence of
genetic, anatomical, and pathological
connections between the two conditions.
Studies have identified a genetic overlap
between symptomatic BPH and prostate
cancer,10,11 while 5-alpha-reductase
inhibitors used to treat symptomatic benign
prostatic disease appear to be effective in
preventing prostate cancer.12,13 Studies have
also identified both fast-growing BPH and
bacterial prostatitis as risk factors for
clinical prostate cancer.14–16
That said, no causal link has been
demonstrated. Observed epidemiological
associations between prostate cancer and
previous benign disease may not relate to
any aetiological association, but rather to
the increased interaction with health
services among patients with benign
disease, and greater expectation of PSA
testing, resulting in a greater likelihood of
cancer being detected.7,17,18
There is a need for research that helps to
clarify whether the concerns of patients are
well founded and whether men with benign
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Abstract
Background
Benign diseases of the prostate are common in
the general male population, and prostate
cancer is the most common cancer in men.
Uncertainty as to the nature of the association
between benign andmalignant disease is a
source of concern for patients and clinicians.
Aim
To determine the likelihood of men with benign
prostate disease developing prostate cancer
compared with men without disease.
Design
Incident matched case–control study
Method
All incident cases of prostate cancer (n = 984)
were identified in a nationally representative
community-based population, and each was
matched by age with two controls with no
prostate cancer (n = 1968). Participants’ records
of the previous 5 years were searched for
diagnoses of benign prostate disease. Analyses
investigated an a priori hypothesis that
clinicians may record disease as benign until
proven to be malignant, causing misleading
significant associations between benign and
malignant diagnoses.
Results
There was a significant association between a
diagnosis of prostate cancer and a benign
diagnosis at any time in the previous 5 years:
odds ratio (OR) 1.57 (95% confidence interval
[CI] = 1.32 to 1.88). However, there was no
significant association when benign diagnoses
within 6months and within 12months of
cancer diagnoses were excluded: OR 1.19 (95%
CI = 0.97 to 1.46) and OR 1.00 (95% CI = 0.79 to
1.27) respectively.
Conclusion
Findings from this study suggest that unless
prostate cancer is detected within 6 months,
men diagnosed for the first time with benign
disease are at no greater risk of prostate
cancer than those with no recorded prostate
disease.
Keywords
primary health care; prognosis; prostatic
hyperplasia; prostatic neoplasms; prostate-
specific antigen.
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disease ought to consider being tested for
cancer more readily than others.
Considered in combination with other
clinical indicators, the PSA test is
increasingly used and it has led to prostate
cancers being diagnosed earlier and an
increase in recorded incidence.19–21
However, the test also yields considerable
numbers of false positives, which can, in
turn, lead to unnecessary anxiety and
potentially risky biopsies.22 Furthermore,
there remains considerable debate as to
whether early detection is beneficial.23,24
Providing advice about PSA testing and
test results presents a considerable
challenge to primary care physicians,22 and
further evidence is desirable that clarifies
the relationship, if any, between benign and
malignant disease.17,25 This study sought to
assess, over 5 years, in an unselected and
representative Scottish community-based
population, whether there is an association
between diagnoses of benign prostate
disease and prostate cancer.
METHOD
The sampling frame for this study was all
men registered with 40 GP surgeries
located throughout Scotland. These clinics
contribute data to the Primary Care Clinical
Informatics Unit and participate in the
quality-assured Practice Team Information
project operated by the NHS Information
Services Division.26 The completeness of
recording of consultations and the accuracy
of data encoding in GP clinics, using the
Read Code system, has been found to be
above 91%.27
To create a primary–secondary care-
linked research database, primary care
patient data were linked in May 2007 with
hospital-based specialist secondary care
data held on the Scottish Morbidity Record
(SMR01) databases hosted by the
Information Services Division. Secondary
care data have been found to be reliable
from1981, with completeness and accuracy
rates exceeding 90%.28
The total patient population within the
database (n = 238 064) is broadly
representative of the Scottish population,
with respect to age, sex, and social
deprivation.29 The postcode of each patient
was used to assign a deprivation status on a
10-point scale, which was then converted to
quintiles for analysis (1 = most affluent to 5
= most deprived). The assigned deprivation
scores were derived from the Scottish Index
of Multiple Deprivation, the Scottish
Government’s official tool for identifying and
coding levels of deprivationnationally,which
uses 37 indicators of poverty across seven
domains (current income, employment,
health, education, housing, access to
services, and crime).30,31
An incident-matched case–control study
was conducted to determine the likelihood
of men with benign prostate disease
developing prostate cancer, compared with
men without recorded prostate disease.
From the anonymised linked database, all
men who were diagnosed with prostate
cancer over a 4-year period (1 January 2003
to 31 December 2006) were identified (Read
Codes B46, B834, and International
Classification of Diseases version 10 codes
233.4 , 185, C61).
Electronic records of cases were checked
backwards, for as long as records existed,
for any previous recorded history of the
condition prior to the date of the index
episode. Individuals with a previous relevant
record were excluded from the study. Those
without a previous record were deemed to
have experienced an incident (first-ever)
diagnosis of prostate cancer on that date.
Age is the most significant risk factor for
both benign and malignant prostate
disease. Each incident prostate cancer case
was therefore matched by age with two
controls, men with no cancer diagnosis on
the same date, selected randomly from the
practice population. Diagnosis dates of the
cases were considered the index dates for
the controls.
Records of both cases and controls were
then checked for the 5 years previous to the
index date for a previous diagnoses of
benign prostate disease (BPH or prostatitis;
Read Codes K20, K21z). Data on bodymass
index (BMI), whether themanwas known to
be a smoker, and deprivation, which are all
How this fits in
This study provides empirical information
for men affected by benign prostate
disease and their physicians. Some degree
of uncertainty persists as to whether any
link exists between benign andmalignant
prostate disease. Yet for men affected by
benign disease, this is a considerable
cause of concern and they are more likely
than unaffected men to expect to be tested
for cancer. This study suggests that among
men diagnosed for the first time in primary
care with prostate disease, unless a
diagnosis of malignant disease is
confirmed within 6 months, the incidence
of subsequent diagnoses of prostate
cancer is low and the risk of prostate
cancer is not significantly higher than in
men with no recorded prostate disease.
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potentially important confounders, were
extracted from the records at the index date.
Men were only regarded as current
smokers when data were available, with
missing-data cases regarded as non-
smoking.
Statistical analysis
Descriptive statistics are presented for
continuous and categorical variables. A
conditional logistic regressionmodel for two
controls per case was fitted to determine
odds ratios (ORs) for diagnoses of benign
disease within the preceding 5 years
associatedwith a prostate cancer diagnosis,
compared with no such diagnosis.
Regardless of physicians’ suspicions, and
until proven to be malignant, diagnoses of
prostate disease may first be recorded as
benign. To consider and to mitigate the
influence of this recording behaviour, it was
decided a priori that analyses should be
performed in several steps: first including
the whole cohort and subsequently
excluding benign diagnoses within 6 and
then within 12months of the index date.
Analyses were conducted using SPSS
(version 16.0).
Sample size calculations
With definitions of benign prostate disease
differing between studies, and few studies
reporting the prevalence of both benign and
malignant disease in the same population,
estimating the required sample size
presents difficulties. Prevalence estimates
forBPHof 83%and67%havebeen reported
inmenwith prostate cancer and high risk of
prostate cancer.9
A previous Scottish primary care study
determined prevalence estimates for
clinically symptomatic BPH in the general
male population of 20.2% in men aged
40–64 years and 42.8% in men aged
65–79 years.32 Other studies have reported
up to 50% of all men over 80 years
experiencing symptomatic BPH.33–35 Taking
the latter higher estimate for BPH
prevalence of 50% in the general male
population and lower estimate of 67% in
high-cancer-risk patients, this might
suggest the prevalence of prior BPH is
some 35% greater in prostate cancer cases
than in the general male population: an OR
of approximately 2.00. To give an 80%power
to detect a significant OR of 2.00 with 95%
confidence intervals (CIs), with controls
among whom prevalence is estimated at
the lower 20% level, it was estimated that a
sample of 126 cases and 252 controlswould
be necessary; to detect an OR of 1.50, a
sample of 395 cases and 790 controlswould
be necessary.36
RESULTS
In the practice population, 984 men were
identified with a first diagnosis of prostate
cancer between 1 January 2003 and 31
December 2006; each case (n = 984) was
matched with two controls (n = 1968). The
characteristics of cases and controls are
presented in Table 1. There was little
difference between cases and controls in
terms of BMI, smoking status, and
socioeconomic status. Levels of missing
data for BMI were similar between cases
and controls. Figure 1 plots the cases by 10-
year age group comparedwith national data
for new cases of prostate cancer
2001–2005.37 The identification of cases,
controls, and previous benign prostate
disease diagnoses in the two groups is
e686 British Journal ofGeneral Practice, November 2011
Table 1. Age, known smoking status, bodymass index, and
socioeconomic status of cases and controls at the index date
Cases (n = 984) Controls (n = 1968)
Mean (SD) age in years 72.8 (9.3) 72.8 (9.3)
% (n) recorded as smokers at index date 13.7 (135) 14.6 (287)
Mean (SD, n) body mass index 23.4 (6.3, n = 815) 23.8 (5.9, n = 1741)
% (n) socioeconomic status: SIMD
1 (most affluent) 13.0 10.5
2 8.2 7.1
3 13.3 12.0
4 9.8 10.1
5 11.6 10.1
6 13.6 15.1
7 9.7 11.3
8 7.7 9.6
9 7.8 9.2
10 (most deprived) 5.3 5.0
Cases = men diagnosed with prostate cancer. Controls = men of same age with no cancer diagnosis (two
controls per case) on date of case's diagnosis. SIMD = Scottish Index of Multiple Deprivation.
illustrated schematically in the flow chart
(Figure 2).
Results of conditional logistic regression
used to consider the association between a
diagnosis of prostate cancer and a prior
diagnosis of benign prostate disease are
presented in Table 2. Whereas there was a
significant association between prostate
cancer and a prior diagnosis of benign
diseasewhen all previous benign diagnoses
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Figure 1. Prostate cancer (new cases) 2001-2005 by 10-year
age group: study cases versus Scottish national data cases
(Information Services Division).
Benign disease
0–60 months previously
n = 216 (22%) of cases
n = 275 (14%) of controls
No benign disease
0–60 months previously
n = 768 (78%) of cases
n = 1693 (86%) of controls
Incident prostate cancer
cases identified
n = 984
2 x cancer-free controls per
case identified
n = 1968
Analysis 1. Outcome: benign disease at any time in previous 5 years
Benign disease
6–60 months previously
n = 140 (14%) of cases
n = 236 (12%) of controls
No benign disease
6–60 months previously
n = 844 (86%) of cases
n = 1732 (88%) of controls
Incident prostate cancer
cases identified
n = 984
2 x cancer-free controls per
case identified
n = 1968
Analysis 2. Outcome: benign disease 6 months to 5 years previously
Benign disease
12–60 months previously
n = 102 (10%) of cases
n = 214 (10%) of controls
No benign disease
12–60 months previously
n = 882 (90%) of cases
n = 1764 (90%) of controls
Incident prostate cancer
cases identified
n = 984
2 x cancer-free controls per
case identified
n = 1968
Analysis 3. Outcome: benign disease 12 months to 5 years previously
Figure 2. Steps in data analysis. Cases =men diagnosed
with prostate cancer. Controls =men of same agewith no
cancer diagnosis (two controls per case) on date of case's
diagnosis.
were included, when diagnoses within
6 months of cancer diagnoses were
excluded, there was no longer a significant
association. When benign diagnoses within
12 months of cancer diagnoses were
excluded, the OR was 1.0 (95% CI = 0.79 to
1.27). Mean times from diagnosis of
prostate cancer (or equivalent index date for
controls) to a previous diagnosis of benign
disease are also presented in Table 2.
DISCUSSION
Summary
This study determined a significant
association between a diagnosis of prostate
cancer and a previous diagnosis of benign
disease at any time in the preceding 5 years.
However, in an a priori planned exclusion of
those whose recorded previous benign
diagnoseswerewithin the 6months and the
12months immediately preceding their first
cancer diagnoses, no significant association
was detected between diagnosis of prostate
cancer and a prior diagnosis of benign
prostate disease. A likely explanation is that
for a proportion of those whose benign
diagnosis is followed by a cancer diagnosis
in the subsequent few months, the benign
diagnosis may be a misdiagnosis or a
‘working diagnosis’ in those being clinically
followed up. The data from this study
indicate that if cancer is not detected within
6 months, most diagnoses of benign
prostate disease in a representative,
community-based population are not
associated with an increased risk of
subsequent prostate cancer.
Strengths and limitations
Amajor strength of the studywas the use of
a large incident case–control cohort of
patients that included, insofar as is possible,
everynewcaseof prostate cancer in awhole
population in a given timeperiod. The risk of
selection bias is therefore low. Other key
strengths include the fact that cases and
controls were selected from the same
population and that it was possible to
account for a range of relevant potential
confounders. The use of a linked
primary–secondary care dataset was also
an important strength, as it thereby allowed
a comprehensive assessment of patient and
healthcare interaction. The study
demonstrates that linked clinical datasets
provide an important opportunity to study
aetiology and prognosis quickly and cost-
effectively.
The definition and diagnosis of BPH and
prostatitis is challenging. These diseases
are the subject of debates among urologists
and other medical disciplines. A pragmatic
approach was adopted to the definition of
BPH and identification of cases that reflects
routine practice in primary care: the BPH
population included men who have
presentedwith and have been diagnosed as
having prostatic enlargement, with or
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Table 2. Previous diagnosis of benign prostate disease formenwith
a diagnosis of prostate cancer (cases) comparedwith thosewithout
(controls), and time between diagnoses
Cases Controls
(n = 984) (n = 1968) Odds ratio (95% CI)
In prior 5 years
Number (%) with no benign 768 (78.0) 1693 (86.0) Reference group
prostate disease
Number (%) with benign 216 (22.0) 275 (14.0) 1.57 (1.32 to 1.88)
prostate disease
Mean (SD) time (months) between 16.9 (16.7) 25.4 (16.6)
index data and benign diagnosis
>6 months to 5 years previously
Number (%) with no benign 844 (85.8) 1732 (88.0) Reference group
prostate disease
Number (%) with benign 140 (14.2) 236 (12.0) 1.19 (0.97 to 1.46)
prostate disease
Mean (SD) time (months) between 24.7 (16.0) 29.1 (14.9)
index data and benign diagnosis
>12 months to 5 years previously
Number (%) with no benign 882 (89.6) 1764 (89.6) Reference group
prostate disease
Number (%) with benign 102 (10.4) 214 (10.4) 1.00 (0.79 to 1.27)
prostate disease
Mean (SD) time (months) between 30.1 (13.7) 31.7 (13.5)
index data and benign diagnosis
without lower urinary tract symptoms, as
well as those whose BPH has been
confirmed histologically. Continuing debate
as to their optimal use has resulted in
inconsistent use and recording of PSA
testing, with patient self-selection and
physician selection introducing an unknown
confounding influence. Thus, this study has
not attempted to analyse different BPH
diagnostic subgroups.
Although 5 years of clinical data were
available for use in searching for prior
diagnoses of benign disease for each case
or control, it is possible that this may not be
fully sufficient to determine the risk of a
disease like prostate cancer, which may be
relatively indolent. However, this period of
time does represent a timescale that is
relatively rare in studies including
community-based cohorts of all cases
within primary care practice populations,
and is equivalent to that used in other
longitudinal studies.38
The effect of treatments after diagnosis
was not considered because data were not
available about contraindications, illness
severity, patient preferences, or adherence
to treatments, all ofwhichcontribute toboth
prescribing patterns and prognostic risk.
Residual confounding due to treatment and
indication bias, therefore, could explain
some of the study findings. It is regrettable
that no data were available about
race/ethnicity or family history, although
there is no reason to suspect difference
between cases and controls in this respect.
Finally, as with all observational research,
some findings may have occurred as a
result of residual confounding.
Comparison with existing literature
Epidemiological studies have suggested
that benign prostatic disease and prostate
cancer are often associated and share
certain predisposing factors.7 However, it
has also been suggested that these
associations may result from a higher
likelihood of identifying prostate cancer in
patients already being observed for benign
disease and that there is no aetiological
association.17,18 The relationship between
the two conditions remains uncertain and a
cause for concern among patients and
physicians alike, and there have been calls
for studies that can assess the risk of
subsequent prostate cancer in men with
benign prostate disease.17,25
This case–control study is the first to use
linked primary–secondary care datasets to
consider the relationship. It sought to
assess the association between the two
diseases in a large and representative
community-based population. The mean
age in the cases identified for the study was
72.8 years, in keeping with the mean age of
prostate cancer diagnosis in the UK, which
is 70–74 years.39 The age-group profile of
the study cases also closely matched the
age-group profile of newly identified
prostate cancer cases in all of Scotland
between 2001 and 2005 (Figure 1).37 The risk
of prostate cancer is strongly related to age:
in the UK, the incidence rate is estimated to
be 144/100 000 in men aged 55–59 years,
500/100 000 in men 65–69 years, and
789/100 000 in men over 85 years:37,40–42 a
trend confirmed by autopsy data.43,44
This study tested the hypothesis that
some recorded diagnoses of benign
disease may in reality indicate the early
stages of a patient’s interaction with health
services and of the diagnostic process for
prostate cancer, with presentations being
recorded as benign that would
subsequently be confirmed as malignant.
Whether benign prostate disease is a
‘working diagnosis’ where a physician
suspects malignancy but records a
tentative diagnosis until confirmation, or
whether an unwittingly inaccurate
diagnosis, such records portray changes in
diagnosis rather than disease progression,
and could lead to erroneous associations in
epidemiological research.
The study data indicate that, among men
with prostate symptoms that are sufficiently
bothersome to result in a primary care
consultation, and a diagnosis of benign
disease, those whose disease is in fact
malignant are likely to be diagnosed within
the first 6months after presentation. If not
diagnosed with cancer at 6months after
diagnosis of benign disease, the risk of a
subsequent diagnosis of prostate cancer is
no longer statistically significantly higher
than it is for men with no previously
recorded prostate disease, and at 1 year the
risk appears to be even. The study confirms
and extends previous work that has found
no true association between the two
diseases, and provides further reassurance
to both patients and clinicians about the
prognosis for men with benign prostate
disease.
Implications for practice
Physicians treating patients with symptoms
of prostate should be reassured that inmen
where a diagnosis of prostate cancer is not
confirmed in the first 6months, there is no
significantly increased risk of prostate
cancer when compared with patients
without these symptoms.
The study data suggest that any higher
British Journal ofGeneral Practice, November 2011 e689
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incidence of malignancy observed in those
with a recent diagnosis of benign disease is
likely to represent misdiagnosis or the
possibility of rapidly evolving disease.
Clinicians should therefore remain vigilant
about the possibility of those who are first
presenting or have recently presented with
apparently benign prostate disease.
Among men diagnosed for the first time
in primary care with prostate disease,
unless a diagnosis of malignant disease is
confirmed within 6 months, the incidence of
subsequent diagnoses of prostate cancer is
low and the risk of prostate cancer is not
significantly higher than in men with no
recorded prostate symptoms. 
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